Article Information
History
- February 22, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Cassandra M Calabrese, DO1,
- Elizabeth Kirchner, DNP1,
- Elaine M Husni, MD1,
- Brandon P Moss, MD2,
- Anthony J Fernandez, MD PhD3,
- Yuxuan Jin, MS4 and
- Leonard H Calabrese, DO1,*
- 1Department of Rheumatic and Immunologic Diseases, Cleveland Clinic
- 2Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic
- 3Department of Dermatology, Cleveland Clinic
- 4Quantitative Health Sciences, Cleveland Clinic
- ↵*Corresponding author: Leonard H. Calabrese, D.O., Professor of Medicine, Cleveland Clinic Lerner, College of Medicine of Case Western Reserve University, RJ Fasenmyer Chair of Clinical Immunology, Department of Rheumatic and Immunologic Diseases, 9500 Euclid Avenue, Desk A50, Cleveland, Ohio 44195, Phone: (216) 444-5258, Fax: (216) 445-7569; email: calabrl{at}ccf.org
Posted February 22, 2022.
Breakthrough SARS-CoV-2 infections in immune mediated disease patients undergoing B cell depleting therapy
